Back to all news

ZYUS To Acquire Clinical Software Platform from Ehave

Mar. 25, 2019

Assets to further enhance ZYUS cannabinoid clinical trial program

SASKATOON, Saskatchewan (March 25, 2019): ZYUS Life Sciences Inc. (“ZYUS” or the “Company”) has entered into a definitive asset purchase agreement (the “Agreement”) with Ehave, Inc. (OTCQB: EHVVF) (“Ehave”) for ZYUS to acquire a proprietary health informatics platform (the “Platform”). The total purchase price of CAD $3.2 million will be paid in cash, as well as stock equating to just under one percent of ZYUS’ currently outstanding shares.

The Platform contains components specifically designed to be used by medical cannabis patients to efficiently gather and verify patient-reported outcomes and experiences, evaluate treatment progress, enhance patient engagement and improve data modeling.

“One of the greatest hurdles faced by patients and clinicians is the lack of a clinical framework to provide effective and reliable dosing and administration regimes,” said Brent Zettl, Chief Executive Officer of ZYUS. “This Platform will be seamlessly incorporated into our clinical trial program and be a valuable tool for the collection of high-quality data that can be shared with patients and clinicians to validate efficacy in cannabinoid-based medicine, further strengthening ZYUS’ position as a leader in cannabinoid therapeutics.”

Closing of the acquisition remains subject to the satisfaction of customary closing conditions, including applicable regulatory approvals, and the approval of Ehave shareholders.

About ZYUS Life Sciences Inc.

ZYUS is a Canadian-based, globally focused biopharmaceutical company that offers patients cannabinoid and other phyto-therapeutic medical solutions. Through our buildout of high margin Canadian and international GMP extraction facilities, global distribution partners, advanced clinical research and IP development, we will deliver high-quality oils, gelcaps, topical creams and other therapeutic formulations to patients worldwide.

At ZYUS, we are shifting the paradigm from the treatment of physical disease to caring for overall well-being by accelerating adoption of cannabinoids as a medical solution. To achieve this, we are investing in clinical research, advancing manufacturing, defining scientific standards, delivering leading education and support, and raising awareness of medical need across the industry.

ZYUS: Advancing the Science of Well-Being™

Please visit

For Additional Information:

Media enquiries:

Dara Willis, ZYUS
Mobile: 416-836-9272

Investor enquiries:

Allan Fowler, ZYUS

Forward-Looking Information

This news release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of ZYUS to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These forward-looking statements include, but are not limited to, statements relating to ZYUS’ expectations with respect to the expected closing date for the acquisition, the utility of the acquired technology to patients, clinicians and researchers and the ability of the acquired technology to improve patient outcomes and quality of life, successful closing of the contemplated transaction and the impact the technology will have on ZYUS’ clinical trial program and position in industry. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the parties to the asset purchase agreement being unable to obtain the necessary director, shareholder and regulatory approvals in a timely manner or at all; (ii) the failure of any closing conditions to the asset purchase agreement to be satisfied; and (iii) the newly acquired technology being effective in clinical trials, improving patient outcomes and impacting ZYUS’ position within the cannabinoid-therapeutics industry. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this press release. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties.

Actual results could differ materially from those currently anticipated due to a number of factors and risks. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. ZYUS does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

Multimedia Files: